Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chris Packard

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Atherosclerosis. Supplements|March 1, 2006
A triumvirate of targets in the prevention and treatment paradigm for cardiovascular diseaseChris Packard
Expert Review of Cardiovascular Therapy|April 14, 2015
Did we IMPROVE-IT: thoughts on LDL targeting post-trial?Chris Packard, Tanya Stezhka
Clinical Cardiology|January 24, 2003
New dimension of statin action on ApoB atherogenicityM John Chapman, Muriel Caslake, Chris Packard, et al.
Biochemical Pharmacology|June 23, 2009
A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and developmentLei Zhao, Weijun Jin, Daniel Rader, et al.
Heart (British Cardiac Society)|April 2, 2021
Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challengesChris Packard, M John Chapman, Mahendra Sibartie, et al.
European Journal of Preventive Cardiology|October 15, 2025
Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductionsElias Björnson, Chris Packard, Martin Adiels, et al.
European Heart Journal|April 17, 2010
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-upDavid Preiss, Paul Welsh, Heather M Murray, et al.
Current Medical Research and Opinion|October 7, 2004
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapyJames Shepherd, Chris Packard, Thomas W Littlejohn, et al.
Heart (British Cardiac Society)|February 18, 2011
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivationJennifer Logue, Heather M Murray, Paul Welsh, et al.
European Heart Journal|September 4, 2012
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPSPaul Welsh, Orla Doolin, Peter Willeit, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Atherosclerosis. Supplements|March 1, 2006
A triumvirate of targets in the prevention and treatment paradigm for cardiovascular diseaseChris Packard
Expert Review of Cardiovascular Therapy|April 14, 2015
Did we IMPROVE-IT: thoughts on LDL targeting post-trial?Chris Packard, Tanya Stezhka
Clinical Cardiology|January 24, 2003
New dimension of statin action on ApoB atherogenicityM John Chapman, Muriel Caslake, Chris Packard, et al.
Biochemical Pharmacology|June 23, 2009
A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and developmentLei Zhao, Weijun Jin, Daniel Rader, et al.
Heart (British Cardiac Society)|April 2, 2021
Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challengesChris Packard, M John Chapman, Mahendra Sibartie, et al.
European Journal of Preventive Cardiology|October 15, 2025
Genetic modelling of triglyceride-rich lipoprotein/remnant lowering mimics APOC3-silencing and predicts clinically relevant coronary heart disease event reductionsElias Björnson, Chris Packard, Martin Adiels, et al.
European Heart Journal|April 17, 2010
Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-upDavid Preiss, Paul Welsh, Heather M Murray, et al.
Current Medical Research and Opinion|October 7, 2004
Lipid-modifying effects of rosuvastatin in postmenopausal women with hypercholesterolemia who are receiving hormone replacement therapyJames Shepherd, Chris Packard, Thomas W Littlejohn, et al.
Heart (British Cardiac Society)|February 18, 2011
Obesity is associated with fatal coronary heart disease independently of traditional risk factors and deprivationJennifer Logue, Heather M Murray, Paul Welsh, et al.
European Heart Journal|September 4, 2012
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPSPaul Welsh, Orla Doolin, Peter Willeit, et al.
Pageof 3